Shire, UCB sales and marketing update

Shire will acquire exclusive, worldwide rights to UCB's ADHD drug Equasym methylphenidate IR and XL for an upfront cash payment of €55 million ($70.1 million). The deal excludes the U.S., Canada and Barbados. Outside of those territories, the XL and IR versions of the drug are marketed in 10 and four countries, respectively, and had combined 2008 net sales of €16.9 million ($21.5 million). As part of the deal, 20 sales employees will transfer to Shire. ...